What ARGOS THERAPEUTICS INC's executives and directors are doing with their own shares, from SEC Form 3/4/5 filings — separating what the filings state (awards, withholding, disclosed plans) from what only the pattern of dates shows.
| 3 months | 12 months | |
|---|---|---|
| Open-market buys | 0 | 0 |
| Sells | 0 | 0 |
| Total trades | 0 | 0 |
| 3 months | 12 months | |
|---|---|---|
| Acquired | 0 | 0 |
| Disposed | 0 | 0 |
| Net activity | +0 | +0 |
View rich charts and dive into the patterns of specific insiders — who is accumulating, who is winding down, and which sale explanations the filings actually support.
| Insider | Relation | Date | Transaction | Shares | Price | Value | Shares held |
|---|---|---|---|---|---|---|---|
| Nicolette Charles A. | CSO and Vice President of R&D | Apr 25 | Disposition to Issuer · D | −27,150 | — | — | 20,056 |
| Harrelson Lori R. | Vice President of Finance | Apr 25 | Disposition to Issuer · D | −22,629 | — | — | 11,776 |
| Katz Richard D | Vice President and CFO | Apr 25 | Disposition to Issuer · D | −22,629 | — | — | 9,697 |
| Abbey Jeffrey D | Chief Executive Officer | Apr 25 | Disposition to Issuer · D | −67,887 | — | — | 25,450 |
| Katz Richard D | Vice President and CFO | Mar 28 | Grant / award · A | +22,629 | — | — | 32,326 |
| Abbey Jeffrey D | Chief Executive Officer | Mar 28 | Grant / award · A | +67,887 | — | — | 93,337 |
| Harrelson Lori R. | Vice President of Finance | Mar 28 | Grant / award · A | +22,629 | — | — | 34,405 |
| Nicolette Charles A. | CSO and Vice President of R&D | Mar 28 | Grant / award · A | +27,150 | — | — | 47,206 |
| Katz Richard D | Vice President and CFO | Jan 10 | Open-market sale · S | −104,435 | $0.16 | −$17.2K | 193,959 |
| Harrelson Lori R. | Vice President of Finance | Jan 10 | Open-market sale · S | −64,329 | $0.16 | −$10.6K | 230,981 |
| Abbey Jeffrey D | President, CEO | Jan 10 | Open-market sale · S | −124,987 | $0.16 | −$20.6K | 510,046 |
| Nicolette Charles A. | CSO and Vice President of R&D | Jan 10 | Open-market sale · S | −100,250 | $0.16 | −$16.5K | 399,990 |
| Katz Richard D | Vice President and CFO | Jan 09 | Open-market sale · S | −104,435 | $0.16 | −$17.2K | 193,959 |
| Abbey Jeffrey D | President, CEO | Jan 09 | Open-market sale · S | −124,987 | $0.16 | −$20.6K | 510,046 |
| Harrelson Lori R. | Vice President of Finance | Jan 09 | Open-market sale · S | −64,329 | $0.16 | −$10.6K | 230,981 |
| Nicolette Charles A. | CSO and Vice President of R&D | Jan 09 | Open-market sale · S | −100,250 | $0.16 | −$16.5K | 399,990 |
| Katz Richard D | Vice President and CFO | Jan 03 | Open-market sale · S | −101,228 | $0.16 | −$16.5K | 298,394 |
| Abbey Jeffrey D | President, CEO | Jan 03 | Open-market sale · S | −114,702 | $0.16 | −$18.7K | 635,033 |
| Abbey Jeffrey D | President, CEO | Jan 03 | Open-market sale · S | −114,702 | $0.16 | −$18.7K | 635,033 |
| Nicolette Charles A. | CSO and Vice President of R&D | Jan 03 | Open-market sale · S | −92,001 | $0.16 | −$15.1K | 500,240 |
Loading...
